Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03033043 · ClinicalTrials.gov registry record · NA
Study of the RelayPro Thoracic Stent-Graft in Subjects With an Acute, Complicated Type B Aortic Dissection
A NA study of Aortic Dissection Type B, sponsored by Bolton Medical.
- Active
- Registry status
- NA
- Development phase
- 56
- Enrollment target
- 20
- Study locations
NCT03033043: Active NA study of Aortic Dissection Type B, sponsored by Bolton Medical.
NCT03033043 is a NA study of Aortic Dissection Type B that is active but no longer recruiting, run by Bolton Medical. The registered enrollment target is 56 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03033043, a NA study of Aortic Dissection Type B, is active but no longer recruiting, sponsored by Bolton Medical.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial is a prospective, multicenter, non-blinded, non-randomized study designed to assess the RelayPro thoracic endografts in the treatment of acute, complicated type B aortic dissection. The primary endpoint will measure all-cause mortality at 30 days post-procedure.
Primary Outcome
All-cause mortality 30 days post-procedure
Conditions Studied
Interventions
- DEVICE Relay Pro Stent-Graft
Study Locations (20)
Connecticut
- Hartford Hospital - Hartford
- Yale School of Medicine - New Haven
Ohio
- University Hospitals - Cleveland
- Cleveland Clinic Foundation - Cleveland
Pennsylvania
- University of Pennsylvania Medical Center / Penn Presbyterian - Philadelphia
- Lankenau Medical Center - Wynnewood
Virginia
- Sentara Heart Hospital - Norfolk
- Carilion Roanoke Memorial Hospital - Roanoke
California
- USC Department of Surgery - Los Angeles
Colorado
- University of Colorado Denver - Aurora
District of Columbia
- Medstar Washington Hospital Center - Washington D.C.
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2017-12-14 |
| Est. Completion | 2026-11 |
| Phase | NA |
What the registry record for NCT03033043 still lists
NCT03033043 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Aortic Dissection Type B appearing as the primary indexed condition, and to 1 intervention - of which Relay Pro Stent-Graft is the first listed.
NCT03033043 names 20 study sites across 16 states, led by Connecticut, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03033043 about?
NCT03033043 is a clinical study titled "Study of the RelayPro Thoracic Stent-Graft in Subjects With an Acute, Complicated Type B Aortic Dissection". This clinical trial is a prospective, multicenter, non-blinded, non-randomized study designed to assess the RelayPro thoracic endografts in the treatment of acute, complicated type B aortic dissection. The primary endpoint will measure all-cause mortality at 30 days post-procedure.
What is the current status of trial NCT03033043?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 56 participants. The study started on 2017-12-14. Estimated completion is 2026-11.
What conditions does trial NCT03033043 study?
This clinical trial studies the following conditions: Aortic Dissection Type B.
What interventions are being tested in trial NCT03033043?
The interventions under investigation include: Relay Pro Stent-Graft (DEVICE).
Who is sponsoring clinical trial NCT03033043?
This trial is sponsored by Bolton Medical, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03033043 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03033043's enrollment target sits among peer trials
56 1262nd of 2000 higher than 737 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI